Fosun Pharma: all 194 studies

Page 1 of 2. Open to participants first (81), then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.Not yet recruitingNCT07889245Phase 2
• Mass Balance Study of [¹⁴C]FXS4640 in Healthy Adult MalesNot yet recruitingNCT07872579Phase 1
• A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07865910Phase 2/3
• Phase II/III Study of FXS5626 in Participants With Non-segmental VitiligoNot yet recruitingNCT07840820Phase 2/3
• A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingNCT07824869Phase 2
• Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11Not yet recruitingNCT07776132Phase 1
• A Phase 1 Study of FXR0906 in Healthy Adults With or Without Elevated TriglyceridesNot yet recruitingNCT07766759Phase 1
• A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous NephropathyNot yet recruitingNCT07765537Phase 1/2
• A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL AmyloidosisNot yet recruitingNCT07765524Phase 1/2
• FXS6837 for the Treatment for IgAN Patients（Longterm Study）Not yet recruitingNCT07750665Phase 2
• A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.Not yet recruitingNCT07747090Phase 3
• QT Interval Effects Study of Oral FXS5626 TabletsRecruitingNCT07695779Phase 1
• A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal HemoglobinuriaEnrolling by invitationNCT07657052Not applicable
• Phase I Study of FXS0683 in the Treatment of Blood TumorsRecruitingNCT07616089Phase 1
• A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.RecruitingNCT07606937Early Phase 1
• A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast CancerNot yet recruitingNCT07601620Phase 1
• A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLCRecruitingNCT07562581Phase 2
• Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid TumorsNot yet recruitingNCT07558200Phase 1
• A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIURecruitingNCT07552012Phase 2
• A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal CancerNot yet recruitingNCT07543471Phase 1
• A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid TumorsRecruitingNCT07541534Phase 1
• A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced TumoursRecruitingNCT07533708Phase 1
• A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid TumorsRecruitingNCT07518043Phase 1
• FXS6837 for the Treatment of IgAN PatientsNot yet recruitingNCT07502638Phase 2
• Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®Not yet recruitingNCT07495930Phase 1
• Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.Not yet recruitingNCT07487519Phase 2
• A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy SubjectsNot yet recruitingNCT07484893Phase 1
• Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid TumorNot yet recruitingNCT07480681Phase 1
• A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Phase 1
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid TumorsRecruitingNCT07473726Phase 1
• A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung CancerRecruitingNCT07459751Phase 2/3
• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT07459738Phase 2
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NECRecruitingNCT07416695Phase 1
• A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal CancerNot yet recruitingNCT07358585Phase 1/2
• Phase I Study of FXS887 in the Treatment of Solid TumorsNot yet recruitingNCT07345637Phase 1
• A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07318883Phase 2/3
• A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic CancerNot yet recruitingNCT07301229Phase 2
• A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat CancerNot yet recruitingNCT07294534Phase 2/3
• A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerRecruitingNCT07294508Phase 2/3
• A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsRecruitingNCT07274813Early Phase 1
• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCRecruitingNCT07269782Phase 2
• A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung CancerRecruitingNCT07253142Phase 2
• Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Phase 1
• Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07115485Phase 2
• Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal CancerRecruitingNCT07106892Phase 2
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active GlomerulonephritisRecruitingNCT07038382Phase 2
• Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1Not yet recruitingNCT07024394Phase 1/2
• FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF AlterationNot yet recruitingNCT07004075Phase 3
• XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS MutationEnrolling by invitationNCT06936527Phase 1/2
• A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT06907615Phase 2
• A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple MyelomaNot yet recruitingNCT06895512Phase 3
• A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT06857279Phase 2
• A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid TumorsRecruitingNCT06848699Phase 1/2
• A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung CancerNot yet recruitingNCT06847334Phase 3
• A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular CarcinomaNot yet recruitingNCT06841185Phase 3
• A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Phase 2
• A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer PatientsRecruitingNCT06832202Phase 2
• A Study of XS-04 in Patients With Relapsed or Refractory Hematologic MalignanciesRecruitingNCT06820268Phase 1
• A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant TumorsRecruitingNCT06769152Phase 2
• A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyRecruitingNCT06769113Phase 2
• A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard TherapyRecruitingNCT06742892Phase 2
• A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Phase 3
• A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.RecruitingNCT06349980Phase 2
• Safety And Efficacy Investigation Of The Effects Of ClearLift Q-Switched Nd:Yag 1064nm Laser Module In The Treatment Of Facial Skin WrinklesNot yet recruitingNCT06349096Not applicable
• A Study of HLX42 in Advanced/Metastatic Solid TumorsRecruitingNCT06210815Phase 1
• A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male SubjectsRecruitingNCT06159101Phase 1
• A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsEnrolling by invitationNCT06115642Phase 1
• Safety and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER:Glass 1540nm Laser Module in the Treatment of Acne Scars.Not yet recruitingNCT06102343Not applicable
• To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCHRecruitingNCT05997602Phase 2
• Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or LymphomaNot yet recruitingNCT05788107Phase 1
• FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerRecruitingNCT05755048Phase 3
• A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E MutationRecruitingNCT05641493Phase 1/2
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 MutationNot yet recruitingNCT05528406Phase 2
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid TumorsNot yet recruitingNCT05442996Phase 1
• Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRCNot yet recruitingNCT05239650Phase 2
• A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCRecruitingNCT05221658Phase 2
• HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid TumorsRecruitingNCT04965220Phase 1
• A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)RecruitingNCT04547166Phase 2/3
• to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT04301739Phase 3
• A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsRecruitingNCT04237805Phase 1/2
• A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard TherapyRecruitingNCT03941574Phase 2
• A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLCCompletedNCT04063163Phase 3Results posted
• Laser Assisted Liposuction and Facial Autologous Fat Grafting With the LipoLife SystemCompletedNCT03800563Not applicableResults posted
• Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast CancerCompletedNCT03084237Phase 3Results posted
• A Phase IIa Study in Primary IgA Nephropathy PatientsCompletedNCT07634744Phase 2
• A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid TumorsActive, not recruitingNCT07160335Phase 1
• The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple AdministrationsActive, not recruitingNCT07035652Phase 1
• A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis BronchiectasisActive, not recruitingNCT06981091Phase 2
• Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and PharmacokineticsActive, not recruitingNCT06980454Phase 1
• FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid NeoplasmsActive, not recruitingNCT06858618Phase 2
• A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLCActive, not recruitingNCT06812260Phase 2
• Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLCActive, not recruitingNCT06569420Phase 3
• Evaluation of Auto-EPAP for Management of Upper Airway Obstruction During Non-Invasive VentilationCompletedNCT06560411Not applicable
• A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy SubjectsCompletedNCT06310746Phase 1
• A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese SubjectsActive, not recruitingNCT06309043Phase 1
• Study of XH-S003 in Healthy VolunteersCompletedNCT06272747Phase 1
• A Phase I Study of XH-S004 in Healthy VolunteersCompletedNCT06236841Phase 1
• A Phase 1 Study of XH-S003 in Healthy VolunteersCompletedNCT05946876Phase 1
• FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform NeurofibromasActive, not recruitingNCT05913037Phase 3
• Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy SubjectsCompletedNCT05902728Phase 1

← Fosun Pharma overview and focus areas